WAVE — Waverley Pharma Share News
0.000.00%
Last trade - 00:00- CA$0.54m
- CA$4.10m
- CA$1.35m
Brief: Waverley Pharma Acquires Us Based Pharmacy
Brief: Waverley Pharma Business Update
Brief: Waverley Pharma Provides Update On Its Parp-1 Inhibitor Program
Brief: Waverley Pharma - Co's Unit Awarded Exclusive Distribution Rights For Two Strengths Of Pemetrexed By NHS England
Brief: Waverley Pharma Gets Tender Award For Capecitabine With NHS Scotland
Brief: Waverley Pharma Announces Tentative ANDA Approval For Pemetrexed In United States
Brief: Waverley Pharma Announces Listing On Frankfurt Stock Exchange
Brief: Waverley Pharma Announces Signing Of Term Sheet
Brief: Waverley Pharma Announces Grant Of Market Authorization For Pemetrexed In Spain And Bortezomib In Italy
Brief: Waverley Pharma Announces Grant Of Market Authorization For Pemetrexed And Bortezomib In Multiple European Countries
Brief: Waverley Pharma Announces Collaboration With Dr. David Herbert And The University Of Manitoba For The Development Of COVID-19 Treatment
Brief: Waverley Pharma Announces Reliance On Relief From Filing Requirements For Annual Financial Statements
Brief: Waverley Pharma Appoints Larry Thiessen As New President & CEO, Effective Feb. 1, 2020
Brief: Waverley Pharma - Resignation Of Pieter De Visser As CFO
Brief: Waverley Pharma Inc Sees Net Revenue Of $200,000 For Quarter Ended Dec. 31, 2018
Brief: Waverley Pharma Announces First Sale Of Generic Oncology Products In U.K
Brief: Waverley Pharma Says CEO George Thomas Resigned
Brief: Waverley Pharma Announces Filing Of Two Abbreviated NDAs In U.S.
Brief: Buffalo Capital says Waverly Pharma's unit entered deal to sell 2 generic cancer drugs